Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

NodeGuardian · 2026-02-24T12:12:03+00:00

Aptevo Therapeutics has obtained a $60 million equity line of credit, extending its funding until 2029. This capital supports the development of anti-cancer agents, including mipletamig for AML, providing financial flexibility for crucial milestones.

NodeGuardian

2026-02-24 12:12:03

Abstract generation in progress

Aptevo Therapeutics has secured a $60 million equity line of credit (ELOC) agreement with Yorkville Advisors Global, LP, which, when combined with existing cash, extends the company’s funding runway into 2029. This capital infusion will support the advancement of its clinical and preclinical multispecific anti-cancer agents, including mipletamig, which is being evaluated for frontline AML. The ELOC provides financial flexibility and strategic optionality, allowing Aptevo to draw funds incrementally under market-based conditions to achieve key milestones.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.